NASDAQ: SGMTSagimet Biosciences Inc Stock
$4.06+0.14 (+3.57%)
Updated Apr 26, 2024
SGMT Price
$4.06
Fair Value Price
$0.01
Market Cap
$129.57M
52 Week Low
$2.13
52 Week High
$20.71
P/E
-1.53x
P/B
1.42x
P/S
28.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.00M
Earnings
-$27.88M
Gross Margin
100%
Operating Margin
-1,393.8%
Profit Margin
-1,393.8%
Debt to Equity
0.06
Operating Cash Flow
-$24M
Beta
2.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGMT Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGMT ($4.06) is overvalued by 40,077.27% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SGMT ($4.06) is not significantly undervalued (40,077.27%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SGMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SGMT due diligence checks available for Premium users.
Be the first to know about important SGMT news, forecast changes, insider trades & much more!
SGMT News
Valuation
SGMT fair value
Fair Value of SGMT stock based on Discounted Cash Flow (DCF)
Price
$4.06
Fair Value
$0.01
Overvalued by
40,077.27%
SGMT ($4.06) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SGMT ($4.06) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SGMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SGMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.53x
Industry
14.88x
Market
41.14x
SGMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
5.85x
SGMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGMT's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
SGMT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SGMT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$96.7M
Liabilities
$5.7M
Debt to equity
0.06
SGMT's short-term assets ($96.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGMT's short-term assets ($96.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.1M
Investing
-$19.6M
Financing
$0.0
SGMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SGMT vs Biotech Stocks
Sagimet Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.